Glucose Metabolism Reprogramming of Immune Cells in the Microenvironment of Pancreatic and Hepatobiliary Cancers
- PMID: 39780341
- DOI: 10.1111/jgh.16873
Glucose Metabolism Reprogramming of Immune Cells in the Microenvironment of Pancreatic and Hepatobiliary Cancers
Abstract
Background and aim: Pancreatic and hepatobiliary cancers are increasing in prevalence and contribute significantly to cancer-related mortality worldwide. Emerging therapeutic approaches, particularly immunotherapy, are gaining attention for their potential to harness the patient's immune system to combat these tumors. Understanding the role of immune cells in the tumor microenvironment (TME) and their metabolic reprogramming is key to developing more effective treatment strategies. This review aims to explore the relationship between immune cell function and glucose metabolism in the TME of pancreatic and hepatobiliary cancers.
Methods: This review synthesizes current research on the metabolic adaptations of immune cells, specifically focusing on glucose metabolism within the TME of pancreatic and hepatobiliary cancers. We examine the mechanisms by which immune cells influence tumor progression through metabolic reprogramming and how these interactions can be targeted for therapeutic purposes.
Results: Immune cells in the TME undergo significant metabolic changes, with glucose metabolism playing a central role in modulating immune responses. These metabolic shifts not only affect immune cell function but also influence tumor behavior and progression. The unique metabolic features of immune cells in pancreatic and hepatobiliary cancers provide new opportunities for targeting immune responses to combat these malignancies more effectively.
Conclusion: Understanding the complex relationship between immune cell glucose metabolism and tumor progression in the TME of pancreatic and hepatobiliary cancers offers promising therapeutic strategies. By modulating immune responses through targeted metabolic interventions, it may be possible to improve the efficacy of immunotherapies and better combat these aggressive cancers.
Keywords: glucose metabolism; immune cell; immunotherapy; tumor microenvironment.
© 2025 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Similar articles
-
Unlocking the potential of chimeric antigen receptor T cell engineering immunotherapy: Long road to achieve precise targeted therapy for hepatobiliary pancreatic cancers.Int J Biol Macromol. 2025 Mar;297:139829. doi: 10.1016/j.ijbiomac.2025.139829. Epub 2025 Jan 13. Int J Biol Macromol. 2025. PMID: 39814310 Review.
-
Metabolic reprogramming and immunological changes in the microenvironment of esophageal cancer: future directions and prospects.Front Immunol. 2025 Jan 24;16:1524801. doi: 10.3389/fimmu.2025.1524801. eCollection 2025. Front Immunol. 2025. PMID: 39925801 Free PMC article. Review.
-
The microbiome and hepatobiliary-pancreatic cancers.Cancer Lett. 2017 Aug 28;402:9-15. doi: 10.1016/j.canlet.2017.05.001. Epub 2017 May 17. Cancer Lett. 2017. PMID: 28527946 Review.
-
The Role of Metabolic Reprogramming in the Tumor Immune Microenvironment: Mechanisms and Opportunities for Immunotherapy in Hepatocellular Carcinoma.Int J Mol Sci. 2024 May 21;25(11):5584. doi: 10.3390/ijms25115584. Int J Mol Sci. 2024. PMID: 38891772 Free PMC article. Review.
-
Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment.Int J Mol Sci. 2024 Nov 14;25(22):12223. doi: 10.3390/ijms252212223. Int J Mol Sci. 2024. PMID: 39596288 Free PMC article. Review.
References
-
- F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.
-
- A. P. Klein, “Pancreatic Cancer Epidemiology: Understanding the Role of Lifestyle and Inherited Risk Factors,” Nature Reviews. Gastroenterology & Hepatology 18, no. 7 (2021): 493–502.
-
- K. E. de Visser and J. A. Joyce, “The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth,” Cancer Cell 41, no. 3 (2023): 374–403.
-
- K. Sobierajska, W. M. Ciszewski, I. Sacewicz‐Hofman, and J. Niewiarowska, “Endothelial Cells in the Tumor Microenvironment,” Advances in Experimental Medicine and Biology 1234 (2020): 71–86.
-
- G. Biffi and D. A. Tuveson, “Diversity and Biology of Cancer‐Associated Fibroblasts,” Physiological Reviews 101, no. 1 (2021): 147–176.
Publication types
MeSH terms
Substances
Grants and funding
- lzuyxcx-2022-177/Medical Innovation and Development Project of Lanzhou University
- 22ZD6FA021-4/Major Science and Technology Projects of Gansu Province
- 82260555/National Natural Science Foundation of China
- 82360510/National Natural Science Foundation of China
- 23JRRA1508/Joint Research Fund General Projects of Gansu Province
LinkOut - more resources
Full Text Sources
Medical